C-reactive protein; a potential marker of second cancer and cardiovascular disease in testicular cancer survivors?

[1]  M. Pencina,et al.  Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. , 2009, JAMA.

[2]  S. Bojesen,et al.  Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[4]  T. Erlinger,et al.  C‐reactive protein and colorectal cancer risk: A systematic review of prospective studies , 2008, International journal of cancer.

[5]  K. Kihara,et al.  Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. , 2008, The Journal of urology.

[6]  M. Mori,et al.  C‐reactive protein as a prognostic marker for men with androgen‐independent prostate cancer , 2008, Cancer.

[7]  S. Palmer,et al.  Cardiovascular risk in long‐term survivors of testicular cancer , 2008, Cancer.

[8]  J. Manson,et al.  C-reactive protein and risk of breast cancer. , 2007, Journal of the National Cancer Institute.

[9]  Wan-Wan Lin,et al.  A cytokine-mediated link between innate immunity, inflammation, and cancer. , 2007, The Journal of clinical investigation.

[10]  P. Hall,et al.  Noncancer causes of death in survivors of testicular cancer. , 2007, Journal of the National Cancer Institute.

[11]  A. Horwich,et al.  Mortality and incidence of second cancers following treatment for testicular cancer , 2007, British Journal of Cancer.

[12]  A. Hofman,et al.  C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  S. Fosså,et al.  Treatment-related differences in cardiovascular risk factors in long-term survivors of testicular cancer , 2006, Journal of cancer survivorship : research and practice.

[14]  F. V. van Leeuwen,et al.  Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  John D Boice,et al.  Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. , 2005, Journal of the National Cancer Institute.

[16]  T. Wilsgaard,et al.  Blood pressure and body mass index in long-term survivors of testicular cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Smit,et al.  The Metabolic Syndrome and Disturbances in Hormone Levels in Long-Term Survivors of Disseminated Testicular Cancer , 2005 .

[18]  H. Bartelink,et al.  Increased carotid wall thickening after radiotherapy on the neck. , 2005, European journal of cancer.

[19]  M. Pfeffer,et al.  C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.

[20]  Vilmundur Gudnason,et al.  C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. , 2004, The New England journal of medicine.

[21]  A. V. van Roon,et al.  Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. , 2004, European journal of cancer.

[22]  S. Fosså,et al.  Increased mortality rates in young and middle-aged patients with malignant germ cell tumours , 2004, British Journal of Cancer.

[23]  A. Mykletun,et al.  Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. , 2003, European urology.

[24]  L. Lind.  Circulating markers of inflammation and atherosclerosis. , 2003, Atherosclerosis.

[25]  D P Dearnaley,et al.  Cardiovascular disease as a long-term complication of treatment for testicular cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  C. McArdle,et al.  Systemic inflammatory response predicts survival following curative resection of colorectal cancer , 2003, The British journal of surgery.

[27]  C. Easterly,et al.  Pathophysiological effects of radiation on atherosclerosis development and progression, and the incidence of cardiovascular complications. , 2002, Medical physics.

[28]  J. Manson,et al.  Is C-Reactive Protein Specific for Vascular Disease in Women? , 2002, Annals of Internal Medicine.

[29]  D. Sleijfer,et al.  Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer , 2000, The Lancet.

[30]  Arthur Gerl, Rudolf Schierl.  Urinary Excretion of Platinum in Chemotherapy-treated Long-term Survivors of Testicular Cancer , 2000, Acta oncologica.